Pipeline™ Vantage Embolization Device With Shield Technology™ for Wide-Necked Intracranial Aneurysms (ADVANCE) (ADVANCE)
A Study of the Pipeline™ Vantage Embolization Device With Shield Technology™ for Endovascular Treatment of Wide-Necked Intracranial Aneurysms
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Baptist Medical Center Jacksonville
-
Miami, Florida, United States, 33136
- Jackson Memorial Hospital
-
-
New York
-
Stony Brook, New York, United States, 11794
- Stony Brook University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria (Imaging):
- Subject has a target intracranial aneurysm located in the internal carotid artery (up to the terminus).
- Subject has a target intracranial aneurysm with an aneurysm neck ≥4mm or a dome-to-neck ratio of < 2.
- Subject has a target intracranial aneurysm that has a parent vessel with diameter 1.5-5.0 mm distal/proximal to the target intracranial aneurysm.
Inclusion Criteria (Clinical):
- Subject (or subject's legally authorized representative) has provided written informed consent using the IRB and Medtronic approved Informed Consent Form and agrees to comply with protocol requirements. HIPAA/data protection authorization has been provided and signed by the subject (or subject's legally authorized representative).
- Age 22-80 years at the time of consent.
- Life expectancy ≥3 years
- Subject has a mRS ≤ 2 at baseline to be determined by a certified independent assessor at the site.
- Subject has already been selected for endovascular treatment of the target aneurysm.
- Subject's last recorded P2Y12 reaction units (PRU) value is between ≥60 and ≤200 prior to study procedure.
- Subject has multiple increased risk factors for intracranial aneurysm rupture, including but not limited to, aneurysm morphology, smoking, hypertension, diabetes, age, prior and/or family history of rupture, and/or history of subarachnoid hemorrhage that may result in a benefit risk profile of endovascular treatment to outweigh the risks of intracranial aneurysm rupture during the subject's expected lifetime if left untreated.
Exclusion Criteria (Imaging):
- Subject has internal carotid artery bifurcation aneurysm.
- Aneurysms that arise from the Posterior Communicating Artery (PComm).
The internal carotid artery aneurysms of the C7 segment will be excluded under the following conditions:
- Observed fetal posterior communicating artery (PComm) of fetal origin (A PComm of fetal origin is defined as a small, hypoplastic, or absent P1 segment of the posterior cerebral artery (PCA) with the PComm artery supplying a majority of blood flow to the P2 and higher order segments of the PCA)
- PComm overlapping with the aneurysm neck
- PComm branch arising from the dome of the aneurysm
- Subject has aneurysm arising from internal carotid artery but is primarily fed by posterior circulation (i.e., retrograde flow from the basilar artery) as confirmed by DSA
Exclusion Criteria (Clinical):
- Subject requires treatment of another aneurysm (with another treatment modality) within the affected territory of the target aneurysm during the study period.
- Subject has received an intracranial implant (e.g. coils) in the area of the target intracranial aneurysm within the past 6 months prior to the study procedure.
- Subject has had a SAH and/or target aneurysm rupture in the past 30 days prior to the study procedure.
- Subject has undergone a surgery including endovascular procedures in the last 30 days prior to the study procedure.
- Aneurysm vessel characteristics (e.g. parent vessel stenosis, irregular morphology) that would preclude the device from fully confirming to the parent vessel to reduce any risk of embolic complications, retreatment, or device movement.
- Subject has active vasospasm, malignant brain tumor or vascular malformation (e.g. arteriovascular malformation).
- History of major bleeding disorder (based on coagulation profile and platelet count) and/or subject presents with signs of active bleeding.
- Subject requires adjunctive device use (e.g. coils) during the index procedure.
- Subject has extradural target aneurysm <12mm which is not symptomatic or not exhibiting aneurysm growth (exception: unless it is a fusiform aneurysm <12 mm i.e., asymptomatic extradural fusiform aneurysms <12 mm can be included).
Any known contraindication to treatment with the Pipeline™ Vantage Embolization Device with Shield Technology™, or use of antiplatelet therapy including:
- Active bacterial infection
- Contraindication to DAPT agents
- Pre-existing stent is in place in the parent artery at the target intracranial aneurysm location
- Platelet count < 100 x 10^3 cells/mm^3 or known platelet dysfunction.
- The Investigator determines that the health of the subject or the validity of the study outcomes (e.g., high risk of neurologic events, conditions that may increase the chance of stroke) may be compromised by the subject's enrollment.
- Subject is pregnant or wishes to become pregnant during the first year of study participation.
- Subject is participating in another clinical trial at any time during the duration of the study that could confound the treatment or outcomes of this investigation.
- Subject with known allergy to platinum or cobalt chromium alloy (including the major elements platinum, cobalt, chromium, nickel or molybdenum).
- History of previous acute ischemic stroke
- Subject is unable to undergo DSA or CTA imaging at follow-up
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Pipeline™ Vantage Embolization Device with Shield Technology™
|
Pipeline™ Vantage Embolization Device with Shield Technology™
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety: Incidence of Major Stroke or Neurological Death
Time Frame: 1 year post-procedure
|
Incidence of major stroke in the territory supplied by the treated artery or neurological death.
|
1 year post-procedure
|
|
Effectiveness: Incidence of Complete Aneurysm Occlusion
Time Frame: 1 year post-procedure
|
Incidence of complete aneurysm occlusion (Raymond Roy Scale Class 1) without significant parent artery stenosis (≤ 50%) or retreatment of the target aneurysm at 1-year post-procedure.
|
1 year post-procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effectiveness: Incidence of Successful Device Implantation
Time Frame: Day 0
|
Incidence of successful device implantation at the target site
|
Day 0
|
|
Safety: Incidence of Major Stroke
Time Frame: 2 and 3 years post-procedure
|
Incidence of major stroke in the territory supplied by the treated artery or neurological death
|
2 and 3 years post-procedure
|
|
Safety: Incidence of Major Stroke
Time Frame: 30 days post-procedure
|
Incidence of major stroke in the territory supplied by the treated artery or neurological death
|
30 days post-procedure
|
|
Safety: Incidence of Delayed Intraparenchymal Hemorrhage
Time Frame: >30 days post-procedure through 1 year post-procedure
|
Incidence of delayed intraparenchymal hemorrhage >30 days post-procedure through 1-year post-procedure
|
>30 days post-procedure through 1 year post-procedure
|
|
Effectiveness: Incidence of Complete Aneurysm Occlusion
Time Frame: 1 year post-procedure
|
Incidence of complete aneurysm occlusion (Raymond Roy Class 1)
|
1 year post-procedure
|
|
Effectiveness: Incidence of Target Aneurysm Recurrence
Time Frame: 1 year post-procedure
|
Incidence of target aneurysm recurrence at 1 year post-procedure
|
1 year post-procedure
|
|
Safety: Incidence of Subjects With Disabling Strokes
Time Frame: Assessed from procedure through 3 years post-procedure
|
Incidence of subjects with disabling strokes that have a mRS decline to a score of 3 or more (mRS ≥ 3) due to a stroke-related cause assessed at a minimum of 90 days post-stroke event
|
Assessed from procedure through 3 years post-procedure
|
|
Effectiveness: Incidence of Complete Aneurysm Occlusion
Time Frame: 3 years post-procedure
|
Incidence of complete aneurysm occlusion (Raymond Roy Class 1)
|
3 years post-procedure
|
|
Effectiveness: Incidence of Target Aneurysm Recurrence
Time Frame: 3 years post-procedure
|
Incidence of target aneurysm recurrence 3-years post-procedure
|
3 years post-procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Pascal Jabbour, MD, Thomas Jefferson University
- Principal Investigator: Demetrius Lopes, MD, Advocate Health
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- COVSHLD0569
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.